A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications

Condition:   Duchenne Muscular Dystrophy Interventions:   Drug: Casimersen;   Drug: Eteplirsen;   Drug: Golodirsen Sponsors:   Kevin Flanigan;   Sarepta Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials